People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Silver Creek Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $12.6M | $139.3M | 2022 |
Lakhmir D. Chawla at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lakhmir D. Chawla on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Marks | 1 | 3 |
| James D. Marks | 1 | 1 |
| Mark Agne | 1 | 1 |
| Kris D. Kuchenbecker | 1 | 1 |
| Nick J. Taylor | 1 | 1 |
| Timothy Throsby | 1 | 1 |
| Thomas J. Murtagh | 1 | 1 |
| Ross Breckenridge | 1 | 1 |
| Michael Fairbanks | 1 | 1 |
| Ulrik Nielsen | 1 | 1 |
| Tom Murtagh | 1 | 1 |
| Birgit Schoeberl | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.